Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

Launched by GENERAL HOSPITAL OF SHENYANG MILITARY REGION · Apr 21, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to give a medication called terlipressin to patients with liver cirrhosis who are experiencing serious bleeding from swollen veins in the esophagus or stomach, a condition known as variceal bleeding. The trial will compare the standard method of giving terlipressin as a quick injection (bolus infusion) to a continuous drip method to see if one is more effective or safer than the other.

To participate in the study, patients must have liver cirrhosis that is classified as moderate to severe (Child-Pugh B or C) and be experiencing acute bleeding from gastroesophageal varices. Unfortunately, those with mild liver cirrhosis (Child-Pugh A), other types of upper gastrointestinal bleeding, or those using certain medications will not be eligible. Participants will be closely monitored throughout the trial, and they will need to provide written consent to join. This study is not yet recruiting participants, but it aims to improve treatment options for people facing this serious health issue.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A diagnosis of liver cirrhosis;
• • 2. Child-Pugh B or C;
• • 3. Acute gastroesophageal variceal bleeding;
• • 4. Written informed consents. -
• Exclusion Criteria:
• • 1. No liver cirrhosis;
• • 2. Child-Pugh class A;
• • 3. Acute upper gastrointestinal bleeding unrelated to varices;
• • 4. Use of somatostatin or octreotide. -